PHS
GILD icon

PFM Health Sciences’s Gilead Sciences GILD Stock Holding History

PFM Health Sciences’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Buy
+90,858
New +$12M 0.98% 38
2026
Q1 		– Sell
-71,018
Closed -$8.72M – 90
2025
Q4 		$8.72M Buy
+71,018
New +$8.63M 0.87% 35
2022
Q2 		– Sell
-249,884
Closed -$14.9M – 83
2022
Q1 		$14.9M Buy
249,884
+172,891
+225% +$11.1M 0.56% 51
2021
Q4 		$5.59M Sell
76,993
-589,608
-88% -$40.6M 0.19% 63
2021
Q3 		$46.6M Hold
666,601
– – 1.37% 32
2021
Q2 		$45.9M Sell
666,601
-408,462
-38% -$27.3M 1.44% 27
2021
Q1 		$69.5M Buy
1,075,063
+133,389
+14% +$8.6M 2.12% 11
2020
Q4 		$54.9M Sell
941,674
-136,415
-13% -$8.23M 1.93% 14
2020
Q3 		$68.1M Buy
1,078,089
+404,677
+60% +$28.1M 3.15% 6
2020
Q2 		$51.8M Buy
673,412
+120,073
+22% +$9.2M 2.69% 7
2020
Q1 		$41.4M Sell
553,339
-798,397
-59% -$55.2M 3.4% 7
2019
Q4 		$87.8M Sell
1,351,736
-492,124
-27% -$32M 4.18% 4
2019
Q3 		$117M Buy
1,843,860
+479,572
+35% +$31.3M 3.45% 6
2019
Q2 		$92.2M Buy
+1,364,288
New +$89.7M 1.75% 15
2016
Q2 		– Sell
-835,032
Closed -$76.7M – 89
2016
Q1 		$76.7M Buy
835,032
+768,845
+1,162% +$69.3M 2.37% 15
2015
Q4 		$6.7M Sell
66,187
-1,059,787
-94% -$110M 0.2% 59
2015
Q3 		$111M Buy
+1,125,974
New +$125M 3.11% 9
2015
Q2 		– Sell
-647,337
Closed -$63.5M – 99
2015
Q1 		$63.5M Sell
647,337
-444,344
-41% -$45.1M 1.75% 21
2014
Q4 		$103M Buy
1,091,681
+259,150
+31% +$26.8M 2.4% 11
2014
Q3 		$88.6M Sell
832,531
-234,424
-22% -$23M 2.04% 20
2014
Q2 		$88.5M Sell
1,066,955
-872,877
-45% -$67.9M 1.77% 21
2014
Q1 		$137M Sell
1,939,832
-1,674,336
-46% -$131M 2.49% 11
2013
Q4 		$271M Sell
3,614,168
-1,516,783
-30% -$106M 5.46% 2
2013
Q3 		$323M Sell
5,130,951
-1,823,537
-26% -$109M 7.77% 1
2013
Q2 		$357M Buy
+6,954,488
New +$362M 7.41% 1

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PFM Health Sciences's GILD Position: Q2 2026 in Review

PFM Health Sciences opened a new position in Gilead Sciences (GILD) in Q2 2026: 90,858 shares worth $11.5M. The stake represents 0.98% of the portfolio and ranks #38 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in GILD as recently as Q4 2025.

PFM Health Sciences first reported a position in GILD in Q2 2013 and has held it in 25 quarters since. The position peaked at $357M in Q2 2013. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • PFM Health Sciences held 90,858 shares of Gilead Sciences worth $11.5M as of Q2 2026.
  • Gilead Sciences was a new PFM Health Sciences position in Q2 2026.
  • Gilead Sciences made up 0.98% of PFM Health Sciences's portfolio in Q2 2026, its #38 holding.
  • PFM Health Sciences first reported a position in Gilead Sciences in Q2 2013 and has held it in 25 quarters since.
  • PFM Health Sciences's Gilead Sciences position peaked at $357M in Q2 2013.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.